This groundbreaking study represents the most comprehensive NMA to date, providing an in-depth analysis of the efficacy of first-line immunotherapy in patients with NS-NSCLC and PD-L1 expression levels ≥ 50%. The gene discussed is CD274; the disease is non-small cell lung carcinoma.